Prascend Tablets (1mg Pergolide) is used for the treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction PPID in Horses (Equine Cushing's Disease). VET PRESCRIPTION REQUIRED
Warning: Last items in stock!
Availability date: 2013-06-07
|Product Name:||1mg Prascend Tablet for Horses (Pergolide) - per Tablet|
|Target Animal:||Horse (Equine)|
|Pet Prescription Required?:||Yes (For UK Orders)|
|Pack Size:||Box of 160|
Prascend may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase Prascend if you have or are in the process of arranging such a prescription. See information bar for further details.
Prascend is a pink modified rectangular shape scored tablet engraved on one side the Boehringer Ingelheim logo and the letters 'PRD' and contains 1.0 mg pergolide (as pergolide mesylate 1.31 mg)
Prascend Tablets are used for the treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction PPID (Equine Cushing's Disease).
Prascend Dosage and administration
Administer Prascend orally once daily at an average starting dose of 2g/kg bodyweight. Studies from the published literature cite the most common average dose as 2g /kg with a range from 0.25 mg - 5 mg total daily dose per horse (0.6 10g/kg). The starting dose (2g/kg) should then be titrated according to the individual response as determined by monitoring (see below). Practical starting doses are recommended as follows: Horse Body Weight Starting Dose Dosage Range Number of Tablets 200 - 400 kg 0.5 mg 1.3 - 2.5g/kg 400 - 600 kg 1.0 mg 1.7 - 2.5g/kg 1 301 - 850 kg 1.5 mg 1.8 - 2.5g/kg 1 851 - 1000 kg 2.0 mg 2.0 - 2.4 g/kg 2 Tablets may be administered orally by dissolving the Prascend tablet with a small amount of water and/or mixing with molasses or other sweetener; taking care to rinse the dosing apparatus with water to ensure entire dose is administered; use immediately. Most horses respond to therapy and are stabilised at an average dose of 2g/kg. Clinical improvement with Prascend is expected within 6 to 12 weeks. Some horses may respond clinically at lower or varying doses and it is recommended to titrate to the lowest effective dose per individual based on response to therapy whether it is effectiveness or signs of intolerance. A small number of horses may require doses as high as 10g/kg per dayof Prascend. In these rare situations appropriate additional monitoring should be implemented. Monitoring and dose titration Pre-treatment samples should be taken for appropriate diagnostic endocrinologic laboratory tests (e.g. serum or plasma ACTH or serum cortisol response to the low-dose dexamethasone suppression test) to diagnosis disease monitor treatment and for dose titration. Following initial diagnosis repeat samples should be taken for endocrinologic testing for dose titration and monitoring of treatment at intervals of 6 weeks until stabilisation of clinical signs and/or diagnostic testing occurs. The approach to treatment is to titrate to the lowest effective dose per individual based on response to therapy whether it is effectiveness or signs of intolerance. Dose titration is based on clinical sign improvement (e.g. hirsutism polyuria polydipsia muscle wasting abnormal fat distribution chronic infections etc.) and/or diagnostic testing improvement/normalisation (e.g. serum ACTH or serum cortisol response to the low-dose dexamethasone suppression test). Depending on the severity of the disease time to treatment response may vary among individuals. For example if clinical signs are not improving or if the diagnostic testing has not yet normalised at the first 6 week interval the total daily dose may be increased by 0.5 mg. Some individuals may be improving but not yet normalised/stabilised and their dose may or may not need to be titrated based on the veterinarian's discretion and the individual's response/tolerance to the Prascend dose.Should clinical signs not be adequately controlled (based on clinical evaluation and/or diagnostic testing) consideration should be given to increasing the total daily dose by 0.5 mg increments every 6 weeks until stabilisation occurs and if Prascend is tolerated at that dose. If signs of dose intolerance develop treatment should be stopped for 2-3 days and reinstituted at one-half the previous dose of Prascend. The total daily dose may be then be titrated back up to the desired clinical effect by 0.5 mg increments every 2-4 weeks. If a dose of Prascend is missed the next scheduled dose should be administered as prescribed. Following stabilisation regular clinical assessment and diagnostic testing should occur every 6 months to monitor treatment and dose.
Prascend for Horses is a POM-V (Pet Prescription Required)